Matthias B Moor
Overview
Explore the profile of Matthias B Moor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
518
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lindberg K, Ovchinnikova O, Moor M, Pirault J, Ketelhuth D, Olauson H, et al.
Atherosclerosis
. 2025 Mar;
403:119158.
PMID: 40054115
Introduction: Components of both the innate and adaptive immune system impact on arterial walls in atherosclerosis. Fibroblast growth factor-23 (FGF23) is a phosphate regulating hormone linked to cardiovascular disease (CVD)...
2.
Anderegg M, Schietzel S, Bargagli M, Bally L, Faller N, Moor M, et al.
Nat Med
. 2025 Jan;
31(1):286-293.
PMID: 39747681
Efficacy of sodium-glucose cotransporter 2 inhibitors for kidney stone prevention in nondiabetic patients is unknown. In a double-blind, placebo-controlled, single-center, crossover phase 2 trial, 53 adults (≥18 and <75 years)...
3.
Nordstrom J, Badia-I-Mompel P, Witasp A, Schwarz A, Evenepoel P, Moor M, et al.
PLoS One
. 2024 Oct;
19(10):e0311613.
PMID: 39471208
Background: Ischemia-reperfusion injury (IRI) inevitably occurs during kidney transplantation and extended ischemia is associated with delayed graft function and poor outcomes. Remote ischemic preconditioning (RIPC) is a simple, noninvasive procedure...
4.
Schietzel S, Limacher A, Moor M, Czerlau C, Huynh-Do U, Vogt B, et al.
BMC Nephrol
. 2024 Oct;
25(1):338.
PMID: 39385105
Background: Inconsistent study results and contradictory recommendations from health authorities regarding the use of apixaban in patients on hemodialysis have generated considerable uncertainty among clinicians, making investigations of appropriate dosing...
5.
Moor J, Toepfner N, von Meissner W, Berner R, Moor M, Kublickiene K, et al.
Biol Sex Differ
. 2024 Sep;
15(1):74.
PMID: 39327617
Background: Sex differences exist not only in the efficacy but also in adverse event rates of many vaccines. Here we compared the safety of BNT162b2 vaccine administered off-label in female...
6.
Bossart S, Daneluzzi C, Moor M, Hirzel C, Heidemeyer K, Seyed Jafari S, et al.
Vaccines (Basel)
. 2023 Sep;
11(9).
PMID: 37766167
cSCC (cutaneous squamous cell carcinoma) and its precursors are a major cause of morbidity, especially in immunosuppressed patients, and are frequently associated with human papillomavirus (HPV) infections. The purpose of...
7.
Strumann C, Ranzani O, Moor J, Berner R, Topfner N, Chao C, et al.
J Clin Invest
. 2023 Sep;
133(21).
PMID: 37669113
No abstract available.
8.
Bartos K, Moor M
Physiol Rep
. 2023 Mar;
11(6):e15650.
PMID: 36967231
Loss of the mediator Of cell motility 1 (Memo1) in mice caused kidney disease and a bone disease with diminished osteoblast and osteoclast biomarkers in serum, resembling alterations occurring in...
9.
Bartos K, Ramakrishnan S, Braga-Lagache S, Hanzi B, Durussel F, Prakash Sridharan A, et al.
J Cell Commun Signal
. 2022 Nov;
17(3):705-722.
PMID: 36434320
Memo1 deletion in mice causes premature aging and an unbalanced metabolism partially resembling Fgf23 and Klotho loss-of-function animals. We report a role for Memo's redox function in renal FGF23-Klotho signaling...
10.
Toepfner N, von Meissner W, Strumann C, Drinka D, Stuppe D, Jorczyk M, et al.
JAMA Netw Open
. 2022 Oct;
5(10):e2237140.
PMID: 36255723
Importance: SARS-CoV-2 vaccines are authorized for use in most age groups. The safety of SARS-CoV-2 vaccines is unknown in children younger than 5 years. Objective: To retrospectively evaluate the safety...